​Our Mission
To make the invisible visible — pioneering real-time, non-invasive imaging of senescent cells transforming how disease progression and treatment efficacy are understood.
We collaborate with innovators advancing medicine to accelerate therapies that improve lives.
Our Story
PreDx was founded in the early 2020s by a team of scientists and visionaries led by Thomas J. Meade, a pioneering Northwestern University professor and serial biotech founder. Their goal: to revolutionize MRI by creating bio-responsive contrast agents that illuminate molecular events — not just anatomy.
​
What began as a bold idea has become a breakthrough reality: MRI agents that respond to senescence-associated β-galactosidase activity, enabling visualization of senescent cells and gene therapy products in vivo.
This capability opens new frontiers in drug development, allowing researchers to quantify biological change over time — from senolytic therapy response to gene delivery success — with unprecedented precision.
Thomas J. Meade, Ph.D. — Founder
Distinguished Northwestern professor across chemistry, molecular biosciences, and biomedical engineering. Founder of five biotech ventures including Clinical MicroSensors (acquired by Roche for $1.8B).
​
Kurt Zoller — Chief Executive Officer
Healthcare marketing leader with deep experience scaling biotech and diagnostics ventures. Former marketing executive at Northwestern Medicine and Epsilon Healthcare.
